Evidence map›Paper›PMID 42714788›Full record

ArticleEndocrine2026

Contemporary management of differentiated thyroid cancer in Latin America: results from the CaTaLiNA prospective multicenter registry.

Paola Solis-Pazmino, Eduardo A Pilatuna, Alison Fernanda Samaniego, Luis A Figueroa, Tannya M Ledesma, Camila N Pazmino-Chavez, Tatiana Rojas, Maria B Tite-Haro, Eddy P Lincango, Nahomi Pazmino and 28 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

38 authors.

Paola Solis-PazminoCaTaLiNA: Cáncer de tiroides en Latinoamérica, Quito, Ecuador.
Eduardo A PilatunaCaTaLiNA: Cáncer de tiroides en Latinoamérica, Quito, Ecuador.
Alison Fernanda SamaniegoCaTaLiNA: Cáncer de tiroides en Latinoamérica, Quito, Ecuador.
Luis A FigueroaCaTaLiNA: Cáncer de tiroides en Latinoamérica, Quito, Ecuador.
Tannya M LedesmaCaTaLiNA: Cáncer de tiroides en Latinoamérica, Quito, Ecuador.
Camila N Pazmino-ChavezCaTaLiNA: Cáncer de tiroides en Latinoamérica, Quito, Ecuador.
Tatiana RojasCaTaLiNA: Cáncer de tiroides en Latinoamérica, Quito, Ecuador.
Maria B Tite-HaroCaTaLiNA: Cáncer de tiroides en Latinoamérica, Quito, Ecuador.
Eddy P LincangoCaTaLiNA: Cáncer de tiroides en Latinoamérica, Quito, Ecuador.
Nahomi PazminoCaTaLiNA: Cáncer de tiroides en Latinoamérica, Quito, Ecuador.
Kamila EscuderoCaTaLiNA: Cáncer de tiroides en Latinoamérica, Quito, Ecuador.
David Toro-TobonCaTaLiNA: Cáncer de tiroides en Latinoamérica, Quito, Ecuador.
Oscar Ponce-PonteCaTaLiNA: Cáncer de tiroides en Latinoamérica, Quito, Ecuador.
Juan P BritoCaTaLiNA: Cáncer de tiroides en Latinoamérica, Quito, Ecuador. Brito.Juan@mayo.edu.ORCID 0000-0003-1840-1745
CaTaLiNA
José Paz-IbarraDivision of Endocrinology, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru.
Victor HernandezDivision of Head and Neck Surgery, Hospital Regional Docente Ambato, Ambato, Ecuador.
Jorge Salazar-VegaDivision of Endocrinology, Hospital Eugenio Espejo, Quito, Ecuador.
Lizbet RuilovaDivision of Endocrinology, SOLCA, Cuenca, Ecuador.
Cristhian GarciaDivision of Head and Neck Surgery, Instituto de la Tiroides y Enfermedades de Cabeza y Cuello, Quito, Ecuador.
Luis ImaicelaDivision of Endocrinology, SOLCA, Guayaquil, Ecuador.
Francisco BonillaDivision of Endocrinology, SOLCA, Quito, Ecuador.
Lenara GolbertDivision of Endocrinology, Santa Casa de Porto Alegre, Porto Alegre, Brazil.
Erika Laurini de Souza MeyerDivision of Endocrinology, Santa Casa de Porto Alegre, Porto Alegre, Brazil.
Magdalena OtazuDivision of Endocrinology, Hospital de Clinicas, Montevideo, Uruguay.
Camilo Gonzalez-VelazquezEndocrinology Division, Department of Internal Medicine, University Hospital "Dr. José E. González", Universidad Autónoma de Nuevo León, Monterrey, Mexico.
Mary VillagomezEndocrinology Division, Department of Internal Medicine, University Hospital "Dr. José E. González", Universidad Autónoma de Nuevo León, Monterrey, Mexico.
Darlyng Patricia Quishpe LópezDivision of Endocrinology, Hospital Eugenio Espejo, Quito, Ecuador.
Melanie Victoria Espin AvilaDivision of Endocrinology, Hospital Eugenio Espejo, Quito, Ecuador.
Diana Carolina Sosa CopaDivision of Endocrinology, Hospital Eugenio Espejo, Quito, Ecuador.
Hilder Herrera-SilvestreDivision of Endocrinology, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru.
Ricardo Anicama-PardoDivision of Endocrinology, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru.
José Somocurcio-PeraltaDivision of Endocrinology, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru.
Paul Fernando Hurtado LeónDivision of Endocrinology, SOLCA, Cuenca, Ecuador.
María Soledad Álvarez ArayDivision of Endocrinology, SOLCA, Cuenca, Ecuador.
Maria Isabel Leon PesantezDivision of Endocrinology, SOLCA, Cuenca, Ecuador.
Raúl Francisco Adolfo Alvarado CorralDivision of Endocrinology, SOLCA, Cuenca, Ecuador.
Jessica CayambeDivision of Head and Neck Surgery, Instituto de la Tiroides y Enfermedades de Cabeza y Cuello, Quito, Ecuador.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInternational guidelines increasingly endorse treatment de-escalation for selected patients with differentiated thyroid cancer (DTC), including thyroid lobectomy and selective use of radioactive iodine (RAI) therapy. How contemporary clinical practice in Latin America aligns with these recommendations remains unclear. We evaluated contemporary management patterns and early outcomes within a large prospective regional registry.

methodsThe Cancer de Tiroides en Latinoamerica (CaTaLiNA) registry is an international, prospective cohort study including patients treated at 11 centers across Ecuador, Peru, Mexico, Brazil, and Uruguay. Adult patients with histologically confirmed DTC undergoing initial thyroid surgery between June 1, 2023, and October 31, 2025, were analyzed. American Thyroid Association (ATA) 2015 risk of structural recurrence and AJCC 8th edition staging were assigned retrospectively. Primary outcomes were the extent of initial surgery, RAI utilization across the ATA risk categories, and early postoperative complications. Multivariable mixed-effects logistic regression was performed to identify factors associated with RAI use and postoperative complications.

resultsA total of 901 patients were included (mean age 47.7 ± 13.3 years; 84.9% women). Papillary thyroid carcinoma accounted for 96.7% of cases. Most patients had early-stage disease (AJCC stage I, 81.5%). Total thyroidectomy was performed in 96.4% of patients. RAI was administered in 54.3% of patients, increasing across risk categories (40.7% low risk, 69.2% intermediate risk, and 59.6% high risk; p < 0.001). Tumor size, resection margin status, and a higher ATA 2015 risk category were independently associated with RAI use. Postoperative complications occurred in 15.4% of patients, predominantly transient hypocalcemia, and were more frequent in higher-risk groups; tumor size was the only independent predictor after adjustment.

conclusionsIn this large Latin American cohort, management of DTC frequently exceeded the intensity recommended by ATA guidelines, with high rates of total thyroidectomy and RAI, including among low-risk patients. The ATA 2015 framework enables more refined risk stratification; however, its integration into clinical practice remains incomplete. These findings provide important region-specific data and highlight opportunities to optimize risk-adapted care and reduce overtreatment in DTC.

Indexed as

Thyroid NeoplasmsAdultFemaleHumansIodine RadioisotopesLatin AmericaMaleMiddle AgedProspective StudiesRegistriesThyroidectomyIodine RadioisotopesATA 2015 guidelinesDifferentiated thyroid cancerLatin AmericaPostoperative complicationsRadioactive iodineThyroidectomy

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.